Endovascular treatment of external iliac artery stenoses for claudication with systematic stenting

Blandine Maurel1, Julien Lancelevee, David Jacobi

  • 1Service de Chirurgie Vasculaire, CHRU de Tours, Tours, France. maurel.blandine@yahoo.fr

Annals of Vascular Surgery
|September 15, 2009
PubMed

Insights

Systematic stenting of external iliac artery lesions effectively treats claudication, showing high patency rates and low complications. This endovascular approach offers satisfying outcomes for patients with this condition.

Area of Science:

  • Vascular Surgery
  • Interventional Cardiology
  • Endovascular Therapeutics

Background:

  • Limited data exists on endovascular treatment outcomes specifically for external iliac artery (EIA) lesions causing claudication.
  • Existing literature often combines claudication and acute ischemia, and does not differentiate between EIA and common iliac artery lesions.
  • The role of systematic stenting for EIA atheromatous lesions remains a subject of debate.

Purpose of the Study:

  • To evaluate the outcomes of systematic stenting for atheromatous lesions of the external iliac artery.
  • To assess results in a consecutive and homogenous population of patients experiencing claudication.
  • To analyze patency rates, complication rates, and clinical outcomes following endovascular treatment.

Main Methods:

  • A cohort of 81 consecutive patients (90 EIA lesions) with claudication underwent systematic stenting between June 2000 and December 2006.
  • Lesions were classified using the Trans-Atlantic Intersociety Consensus (TASC) criteria; endovascular treatment was systematically chosen for TASC A and B, and high-risk TASC C and D.
  • Clinical examinations and duplex ultrasound follow-ups were performed, with a mean follow-up of 23 months.

Main Results:

  • A low complication rate of 2.2% was observed, with no deaths.
  • Primary patency rates were 97% at 1 year, 90% at 2 years, and 84% at 3 years; secondary patency rates were 98% at 1 year, 93% at 2 years, and 93% at 3 years.
  • Most patients became asymptomatic or reported moderate claudication post-treatment; TASC C or D classification trended towards earlier restenosis (p=0.06).

Conclusions:

  • Systematic stenting of external iliac artery atheromatous lesions in patients with claudication yields satisfying clinical results.
  • The study demonstrates high patency rates and a low complication profile in a larger patient cohort than previously reported.
  • Endovascular treatment with systematic stenting is a viable option for managing external iliac artery lesions causing claudication.

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...